JPMorgan analyst David Low reiterated an Overweight rating and $240.00 price target on ResMed (NYSE: RMD)The analyst comments "We expect ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE